AU Patent

AU2022318739A1 — Compositions for use in the treatment of bacterial vaginosis

Assigned to Dare Bioscience Inc · Expires 2024-02-15 · 2y expired

What this patent protects

A pharmaceutical composition for use in the treatment of bacterial vaginosis, wherein said composition comprises a poloxamer, a stabilization polymer, and an active ingredient for treating the bacterial vaginosis, preferably clindamycin, wherein said composition has a viscosity o…

USPTO Abstract

A pharmaceutical composition for use in the treatment of bacterial vaginosis, wherein said composition comprises a poloxamer, a stabilization polymer, and an active ingredient for treating the bacterial vaginosis, preferably clindamycin, wherein said composition has a viscosity of at least 1.5 million mPa.s.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022318739A1
Jurisdiction
AU
Classification
—
Expires
2024-02-15
Drug substance claim
No
Drug product claim
No
Assignee
Dare Bioscience Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.